Taiwan · Delayed Price · Currency is TWD BioLASCO Taiwan Statistics
Total Valuation
BioLASCO Taiwan has a market cap or net worth of TWD 765.80 million. The enterprise value is 710.88 million.
| Market Cap | 765.80M |
| Enterprise Value | 710.88M |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | Aug 7, 2025 |
Share Statistics
BioLASCO Taiwan has 25.61 million shares outstanding. The number of shares has increased by 0.24% in one year.
| Current Share Class | 25.61M |
| Shares Outstanding | 25.61M |
| Shares Change (YoY) | +0.24% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | 29.58% |
| Owned by Institutions (%) | n/a |
| Float | 16.21M |
Valuation Ratios
The trailing PE ratio is 18.12.
| PE Ratio | 18.12 |
| Forward PE | n/a |
| PS Ratio | 2.92 |
| PB Ratio | 1.67 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | 28.30 |
| P/OCF Ratio | 15.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.77, with an EV/FCF ratio of 26.27.
| EV / Earnings | 16.75 |
| EV / Sales | 2.71 |
| EV / EBITDA | 11.77 |
| EV / EBIT | 14.55 |
| EV / FCF | 26.27 |
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.93 |
| Quick Ratio | 3.23 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | 3.01 |
| Interest Coverage | 23.64 |
Financial Efficiency
Return on equity (ROE) is 9.35% and return on invested capital (ROIC) is 10.05%.
| Return on Equity (ROE) | 9.35% |
| Return on Assets (ROA) | 4.98% |
| Return on Invested Capital (ROIC) | 10.05% |
| Return on Capital Employed (ROCE) | 8.92% |
| Weighted Average Cost of Capital (WACC) | 4.98% |
| Revenue Per Employee | 2.89M |
| Profits Per Employee | 466,242 |
| Employee Count | 91 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 4.65 |
Taxes
In the past 12 months, BioLASCO Taiwan has paid 7.14 million in taxes.
| Income Tax | 7.14M |
| Effective Tax Rate | 14.40% |
Stock Price Statistics
The stock price has decreased by -5.59% in the last 52 weeks. The beta is 0.19, so BioLASCO Taiwan's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -5.59% |
| 50-Day Moving Average | 29.76 |
| 200-Day Moving Average | 31.81 |
| Relative Strength Index (RSI) | 56.75 |
| Average Volume (20 Days) | 9,819 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLASCO Taiwan had revenue of TWD 262.66 million and earned 42.43 million in profits. Earnings per share was 1.65.
| Revenue | 262.66M |
| Gross Profit | 104.78M |
| Operating Income | 48.04M |
| Pretax Income | 49.56M |
| Net Income | 42.43M |
| EBITDA | 59.58M |
| EBIT | 48.04M |
| Earnings Per Share (EPS) | 1.65 |
Balance Sheet
The company has 136.41 million in cash and 81.49 million in debt, with a net cash position of 54.92 million or 2.14 per share.
| Cash & Cash Equivalents | 136.41M |
| Total Debt | 81.49M |
| Net Cash | 54.92M |
| Net Cash Per Share | 2.14 |
| Equity (Book Value) | 457.72M |
| Book Value Per Share | 17.59 |
| Working Capital | 157.42M |
Cash Flow
In the last 12 months, operating cash flow was 48.71 million and capital expenditures -21.65 million, giving a free cash flow of 27.06 million.
| Operating Cash Flow | 48.71M |
| Capital Expenditures | -21.65M |
| Depreciation & Amortization | 11.53M |
| Net Borrowing | -16.09M |
| Free Cash Flow | 27.06M |
| FCF Per Share | 1.06 |
Margins
Gross margin is 39.89%, with operating and profit margins of 18.29% and 16.15%.
| Gross Margin | 39.89% |
| Operating Margin | 18.29% |
| Pretax Margin | 18.87% |
| Profit Margin | 16.15% |
| EBITDA Margin | 22.68% |
| EBIT Margin | 18.29% |
| FCF Margin | 10.30% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 4.93%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 4.93% |
| Dividend Growth (YoY) | -9.09% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 90.55% |
| Buyback Yield | -0.24% |
| Shareholder Yield | 4.70% |
| Earnings Yield | 5.54% |
| FCF Yield | 3.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 30, 2018. It was a forward split with a ratio of 1.055.
| Last Split Date | Jul 30, 2018 |
| Split Type | Forward |
| Split Ratio | 1.055 |
Scores
BioLASCO Taiwan has an Altman Z-Score of 5.13 and a Piotroski F-Score of 7.
| Altman Z-Score | 5.13 |
| Piotroski F-Score | 7 |